Document Detail

Kidney flow and function in hypertension: protective effects of pycnogenol in hypertensive participants--a controlled study.
MedLine Citation:
PMID:  20097689     Owner:  NLM     Status:  MEDLINE    
This study evaluated the effects of Pycnogenol as an adjunct to angiotensin-converting enzyme (ACE)-inhibitor ramipril treatment of hypertensive patients presenting with early signs of renal function problems. One group of 26 patients was medicated with 10 mg ramipril per day only; a second group of 29 patients took Pycnogenol in addition to the ACE inhibitor over a period of 6 months. At trial end, a lowered systolic and diastolic blood pressure was found in both groups, with a significant further reduction of diastolic pressure in the group given Pycnogenol in addition to ramipril. The major aim of this study was the investigation of kidney-protective effects of Pycnogenol. Urinary albumin decreased from 87 +/- 23 to 64 +/- 16 mg/d with ramipril only. Additional Pycnogenol lowered albumin significantly better from 91 +/- 25 to 39 +/- 13 mg/day (P < .05). In both groups, serum creatinine was lowered; however, only in the combination treatment group did the effect reached statistical significance. In both groups, CRP levels decreased from 2.1 to 1.8 with ramipril and from 2.2 to 1.1 with the ramipril-Pycnogenol combination; the latter reached statistical significance. Kidney cortical flow velocity was investigated by Doppler color duplex ultrasonography. Both systolic and diastolic flow velocities increased significantly after 6 months medication with ramipril. The addition of Pycnogenol to the regimen statistically significantly further enhanced kidney cortical flow velocities, by 8% for diastolic flow and 12% for systolic flow, relative to values found for the group taking ramipril only. The protective effects of Pycnogenol for initial kidney damage found in this study warrant further research with a larger number of patients and over a longer period of time.
Maria Rosaria Cesarone; Gianni Belcaro; Stefano Stuard; Frank Sch?nlau; Andrea Di Renzo; Maria Giovanna Grossi; Mark Dugall; Umberto Cornelli; Marisa Cacchio; Giuseppe Gizzi; Luciano Pellegrini
Related Documents :
1292579 - Iontophoretically enhanced transdermal delivery of an ace inhibitor in induced hyperten...
6992919 - Absence of blood-pressure lowering effect of captopril in anephric patients.
8961069 - Circadian variation in blood pressure and heart rate in nonhypertensive congestive hear...
11811359 - Inhibition of progression of heart failure and expression of tgf-beta 1 mrna in rats wi...
18449379 - No hope without proof: do arbs meet the standard for cardiovascular protection?
2820329 - A single-blind, randomized, cross-over study of angiotensin-converting enzyme inhibitor...
405339 - Continuous infusion pressure-monitored sialography.
15030069 - Blood pressure control among hypertensives managed in a specialised health care setting...
11475459 - Pneumatic bracing and total contact casting have equivocal effects on plantar pressure ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-01-22
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  15     ISSN:  1940-4034     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-05     Completed Date:  2010-04-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  41-6     Citation Subset:  IM    
Irvine3, Vascular Labs & Microcirculation, Physiology, Department of Biomedical Sciences, G D'Annunzio University, Pescara, San Valentino Vascular Screening Project, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
Antihypertensive Agents / pharmacology*
Creatinine / blood
Drug Therapy, Combination
Flavonoids / pharmacology*
Hypertension / complications,  drug therapy*
Kidney / drug effects*,  physiopathology,  ultrasonography
Kidney Diseases / etiology,  prevention & control*,  ultrasonography
Middle Aged
Platelet Aggregation Inhibitors / pharmacology*
Ramipril / pharmacology*
Treatment Outcome
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Flavonoids; 0/Platelet Aggregation Inhibitors; 0/pycnogenols; 60-27-5/Creatinine; 87333-19-5/Ramipril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The phosphoproteome of the minimal bacterium Mycoplasma pneumoniae: analysis of the complete known S...
Next Document:  Developmental changes in antioxidant enzymatic defences against oxidative stress in sheep placentome...